Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
Intra-Cellular Therapies Analyst Ratings
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
Morgan Stanley Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $95
JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc